Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Status and Forecast 2022

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

Market Analysis and Insights: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market

The global Amyotrophic Lateral Sclerosis (ALS) Treatment market size is projected to reach US$ 478.7 million by 2027, from US$ 277 million in 2020, at a CAGR of 8.1% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market.

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Scope and Market Size

Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Riluzole

Edaravone (Radicava)

Other

Hospital

Drugs Store

Other

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027

1.2.2 Riluzole

1.2.3 Edaravone (Radicava)

1.2.4 Other

1.3 Market by Application

1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2016 VS 2021 VS 2027

1.3.2 Hospital

1.3.3 Drugs Store

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2016-2027)

2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Regions

2.2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions: 2016 VS 2021 VS 2027

2.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Share by Regions (2016-2021)

2.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Regions (2022-2027)

2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Dynamic

2.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends

2.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers

2.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges

2.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints

3.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue

3.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2016-2021)

3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2016-2021)

3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.3 Players Covered: Ranking by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue

3.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio

3.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2020

3.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Area Served

3.6 Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product Solution and Service

3.7 Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2016-2021)

4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2022-2027)

5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2016-2021)

5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2022-2027)

6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2016-2027)

6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type

6.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021)

6.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027)

6.2.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2027)

6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021)

6.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027)

6.3.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2027)

6.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

6.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021)

6.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027)

6.4.3 United States

6.4.4 Canada

7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2016-2027)

7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type

7.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021)

7.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027)

7.2.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2027)

7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021)

7.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027)

7.3.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2027)

7.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

7.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021)

7.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic

8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2016-2027)

8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type

8.2.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021)

8.2.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027)

8.2.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2027)

8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

8.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021)

8.3.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027)

8.3.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2027)

8.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region

8.4.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2016-2021)

8.4.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2022-2027)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2016-2027)

9.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type

9.2.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021)

9.2.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027)

9.2.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2027)

9.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

9.3.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021)

9.3.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027)

9.3.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2027)

9.4 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

9.4.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021)

9.4.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027)

9.4.3 Mexico

9.4.4 Brazil

10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2016-2027)

10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type

10.2.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021)

10.2.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027)

10.2.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2027)

10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

10.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021)

10.3.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027)

10.3.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2027)

10.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

10.4.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021)

10.4.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11.1 Mitsubishi Tanabe Pharma

11.1.1 Mitsubishi Tanabe Pharma Company Details

11.1.2 Mitsubishi Tanabe Pharma Business Overview

11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.1.5 Mitsubishi Tanabe Pharma Recent Development

11.2 Sanofi

11.2.1 Sanofi Company Details

11.2.2 Sanofi Business Overview

11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.2.5 Sanofi Recent Development

11.3 Mylan Pharma

11.3.1 Mylan Pharma Company Details

11.3.2 Mylan Pharma Business Overview

11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.3.5 Mylan Pharma Recent Development

11.4 Apotex

11.4.1 Apotex Company Details

11.4.2 Apotex Business Overview

11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.4.5 Apotex Recent Development

11.5 Glemark Generics

11.5.1 Glemark Generics Company Details

11.5.2 Glemark Generics Business Overview

11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.5.5 Glemark Generics Recent Development

11.6 Covis Pharma

11.6.1 Covis Pharma Company Details

11.6.2 Covis Pharma Business Overview

11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.6.5 Covis Pharma Recent Development

11.7 Sun Pharma

11.7.1 Sun Pharma Company Details

11.7.2 Sun Pharma Business Overview

11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.7.5 Sun Pharma Recent Development

11.8 Lunan Pharma

11.8.1 Lunan Pharma Company Details

11.8.2 Lunan Pharma Business Overview

11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction

11.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

11.8.5 Lunan Pharma Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027

    Table 2. Key Players of Riluzole

    Table 3. Key Players of Edaravone (Radicava)

    Table 4. Key Players of Other

    Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027

    Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027

    Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions (2016-2021) & (US$ Million)

    Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2016-2021)

    Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)

    Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2022-2027)

    Table 11. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends

    Table 12. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers

    Table 13. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges

    Table 14. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints

    Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players (2016-2021) & (US$ Million)

    Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players (2016-2021)

    Table 17. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2020)

    Table 18. Ranking of Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Companies by Revenue (US$ Million) in 2020

    Table 19. Global 5 Largest Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (CR5 and HHI) & (2016-2021)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product Solution and Service

    Table 22. Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021) (US$ Million)

    Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2016-2021)

    Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)

    Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)

    Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2016-2021) & (US$ Million)

    Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2016-2021)

    Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)

    Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)

    Table 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021) (US$ Million)

    Table 33. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027) & (US$ Million)

    Table 34. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021) (US$ Million)

    Table 35. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027) & (US$ Million)

    Table 36. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021) & (US$ Million)

    Table 37. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027) & (US$ Million)

    Table 38. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021) (US$ Million)

    Table 39. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027) & (US$ Million)

    Table 40. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021) (US$ Million)

    Table 41. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027) & (US$ Million)

    Table 42. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021) & (US$ Million)

    Table 43. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027) & (US$ Million)

    Table 44. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021) (US$ Million)

    Table 45. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027) & (US$ Million)

    Table 46. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021) (US$ Million)

    Table 47. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027) & (US$ Million)

    Table 48. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2016-2021) & (US$ Million)

    Table 49. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2022-2027) & (US$ Million)

    Table 50. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021) (US$ Million)

    Table 51. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027) & (US$ Million)

    Table 52. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021) (US$ Million)

    Table 53. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027) & (US$ Million)

    Table 54. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021) & (US$ Million)

    Table 55. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027) & (US$ Million)

    Table 56. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2016-2021) (US$ Million)

    Table 57. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2022-2027) & (US$ Million)

    Table 58. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2016-2021) (US$ Million)

    Table 59. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2022-2027) & (US$ Million)

    Table 60. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2016-2021) & (US$ Million)

    Table 61. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2022-2027) & (US$ Million)

    Table 62. Mitsubishi Tanabe Pharma Company Details

    Table 63. Mitsubishi Tanabe Pharma Business Overview

    Table 64. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 65. Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 66. Mitsubishi Tanabe Pharma Recent Development

    Table 67. Sanofi Company Details

    Table 68. Sanofi Business Overview

    Table 69. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 70. Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 71. Sanofi Recent Development

    Table 72. Mylan Pharma Company Details

    Table 73. Mylan Pharma Business Overview

    Table 74. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 75. Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 76. Mylan Pharma Recent Development

    Table 77. Apotex Company Details

    Table 78. Apotex Business Overview

    Table 79. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 80. Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 81. Apotex Recent Development

    Table 82. Glemark Generics Company Details

    Table 83. Glemark Generics Business Overview

    Table 84. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 85. Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 86. Glemark Generics Recent Development

    Table 87. Covis Pharma Company Details

    Table 88. Covis Pharma Business Overview

    Table 89. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 90. Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 91. Covis Pharma Recent Development

    Table 92. Sun Pharma Company Details

    Table 93. Sun Pharma Business Overview

    Table 94. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product

    Table 95. Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 96. Sun Pharma Recent Development

    Table 97. Lunan Pharma Company Details

    Table 98. Lunan Pharma Business Overview

    Table 99. Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021) & (US$ Million)

    Table 100. Lunan Pharma Recent Development

    Table 101. Research Programs/Design for This Report

    Table 102. Key Data Information from Secondary Sources

    Table 103. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type: 2020 VS 2027

    Figure 2. Riluzole Features

    Figure 3. Edaravone (Radicava) Features

    Figure 4. Other Features

    Figure 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2020 VS 2027

    Figure 6. Hospital Case Studies

    Figure 7. Drugs Store Case Studies

    Figure 8. Other Case Studies

    Figure 9. Amyotrophic Lateral Sclerosis (ALS) Treatment Report Years Considered

    Figure 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027

    Figure 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027

    Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions: 2020 VS 2027

    Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2022-2027)

    Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players in 2020

    Figure 15. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2020

    Figure 16. The Top 10 and 5 Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2020

    Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2016-2021)

    Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2022-2027)

    Figure 19. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 20. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2016-2027)

    Figure 21. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2016-2027)

    Figure 22. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2016-2027)

    Figure 23. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 24. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 25. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 26. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2016-2027)

    Figure 27. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2016-2027)

    Figure 28. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2016-2027)

    Figure 29. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 30. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 31. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 32. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 33. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 34. Nordic Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 35. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 36. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2016-2027)

    Figure 37. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2016-2027)

    Figure 38. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2016-2027)

    Figure 39. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 40. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 41. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 42. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 43. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 44. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 45. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 46. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2016-2027)

    Figure 47. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2016-2027)

    Figure 48. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2016-2027)

    Figure 49. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 50. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 51. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 52. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2016-2027)

    Figure 53. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2016-2027)

    Figure 54. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2016-2027)

    Figure 55. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 56. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 57. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)

    Figure 58. Mitsubishi Tanabe Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 59. Sanofi Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 60. Mylan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 61. Apotex Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 62. Glemark Generics Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 63. Covis Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 64. Sun Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 65. Lunan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2016-2021)

    Figure 66. Bottom-up and Top-down Approaches for This Report

    Figure 67. Data Triangulation

    Figure 68. Key Executives Interviewed